CTI Life Sciences Fund L.P.
Venture capitalMontréal · Seed–Late Stage · 9 people tracked
Investment thesis
Canadian life sciences VC co-created with a major pension fund, acting as a semi-institutional anchor that catalyzes hundreds of millions in follow-on capital despite modest ~$245M fund size.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from public directories
What they invest in
from 10 of 41 portfolio companiesBiotech ×9AI & Machine Learning ×2Digital Health ×2Healthtech ×2Medical Devices ×2AgTech ×1Cleantech ×1Deep Tech ×1
HQs:United States×4Canada×2Denmark×1
Investments · 41 tracked
founders shown can be your intro pathZymeworks develops novel medicines for patients with difficult-to-treat diseases using proprietary platforms and in-house R&D capabilities.
BiotechDigital HealthMedical DevicesVancouver, US
HAIG FARRIS(Director)NOEL HALL(Director)Kenneth Galbraith(Director)inNICK BEDFORD(Director)GORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)
Board seatShermaine Tilley· per SEC Form D
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
First-in-class autophagy-driven treatment for metastatic pancreatic cancer, with promising interim Phase 2b data.
Clinical-stage biotherapeutics company developing mTORC1-specific inhibitors.
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Precision cardiology company built around a Phase 3-ready asset from the Montreal Heart Institute.
Domain Therapeutics develops drug discovery and development therapies that target GPCRs to modulate the immune system, focusing on immuno-oncology and inflammatory diseases.
BiotechDigital Health
Platform designing peptide-based therapies for intramembrane targets, with promising pre-clinical lead asset data.
Webflow is a web design and content management platform that enables teams to create, manage, and optimize custom websites and web applications without heavy developer involvement.
AgTechCleantechDeveloper ToolsEnterprise SoftwareMarketing TechSaaSCopenhagen, DK
Adam Ingwersen(Founder)inFrederik Ingwersen(Founder)in
Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.
San Francisco, US
BiotechDartmouth
James Hall(Director)Julia P. Gregory(Director)Wayne Pisano(Director)Markus Warmuth(Director)Andrew Sheldon(Director)Pierre Labbe(Executive Officer)
Platform producing potential best-in-class assets against GPCR targets with strong pre-clinical data.
Pre-clinical biotech developing the SeekR platform for self-delivering siRNA therapies beyond the liver.
Phenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology.
AI & Machine LearningBiotechDeep TechToronto, CA
Sam Cooper(Co-founder & CTO)Oren Kraus(Co-founder)
MRI-guided ablation improving survival outcomes with a less invasive approach than traditional methods.
First-in-class treatment for the rare pediatric cardiology disease Long QT Syndrome, with strong Phase 2a efficacy.
BiotechWaltham, US
Garry Nicholson(Executive Officer, Director)David Mott(Director)Rakesh Jain(Director)Edward Freedman(Executive Officer)
BoardRobert Langer(Director)Alan Crane(Director)
Exits · 3
IPOs and acquisitions across the tracked portfolioZymeworksNASDAQ: ZYMEProfound MedicalNASDAQ: PROFVaxcyteNASDAQ: PCVX
Portfolio news
latest coverage across their companiesZymeworks · finance.yahoo.com · Jul 1, 2026
Aeovian Pharmaceuticals · bioxconomy.com · Dec 18, 2025
Frequently asked questions
- What stage does CTI Life Sciences Fund L.P. invest at?
- CTI Life Sciences Fund L.P. invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does CTI Life Sciences Fund L.P. focus on?
- CTI Life Sciences Fund L.P. focuses on AI & Machine Learning, Biotech, Healthtech, Medical Devices.
- Where is CTI Life Sciences Fund L.P. located?
- CTI Life Sciences Fund L.P. is headquartered in Montréal, CA.
- Does CTI Life Sciences Fund L.P. lead rounds?
- CTI Life Sciences Fund L.P. typically participates in rounds rather than leading them.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.